There was plenty going on at blockchain technology builder Valereum Blockchain (VLRM) as the Gibraltar based group announced the launch of its the Non-Fungible-Token securities financial platform. The arrival of its financial NFTs is something which is not only a so-called bridge between the fiat and crypto worlds, it creates a new railroad in terms of an asset class. The Company said it will be working with Vinay Gupta's Mattereum to have its first listed company NFT live on a crypto exchange in the coming weeks. Markets to be listed on this new exchange are to range from Alibaba to Zoom and from Chinese debt to US Treasuries. Shares of Valereum Blockchain were up 16%, with investors still in the run up to its OTCQB listing.
Sticking with the Aquis market and CBD and hemp product supplier Love Hemp (LIFE) said it had raised £2.0 million by way of a Subscription of new ordinary shares of 0.1 pence each in the Company at a price of 3.5p per share. The highlight here was that the raise was at a 7.7% premium to the closing price on 25 May 2021. Premium funding prices are traditionally regarded as a show of strong investor confidence in a stock. At the same time the company reported a record day of sales on 20 May 2021 exclusively through its love-hemp.com e-commerce site. Love Hemp’s Drop Day resulted in the brand selling 3,415 units with £86.4k of total sales.
There was more timely newsflow from online threat hunting company Brandshield Systems (BRSD) as it launched VaxFax, the first crowdsourced site letting anyone submit fake vaccine websites, social postings, and marketplace listings to keep others from falling victim to harmful COVID-19 sites and scammers. The company said the launch of VaxFax comes as suspicious COVID-19 vaccine-related web registrations and social media posts have risen sharply since the beginning of the global vaccination rollout. BrandShield has uncovered over 8,000 suspicious new domain names containing the word 'vaccine' and detected nearly 30,000 suspicious social media posts and accounts promoting fake vaccine scams.
Things were moving at Chaarat Gold (CGH). The AIM-quoted gold mining Company with an operating mine in Armenia and assets at various stages of development in the Kyrgyz Republic, offered an updated JORC compliant bankable feasibility study for its Tulkubash Oxide Gold Project. The 2021 BFS confirms robust economics for the development of an open-pit mining heap leach operation. Chaarat said that Infill drilling is planned, as part of the 2021 exploration programme, to focus on converting Inferred resources into Measured and Indicated. This conversion could improve the current 5-year life of mine.
The white knuckle ride continued at specialist lender Amigo (AMGO), with the shares this time down 50% and more at one stage. This decline to 8p came after a peak earlier this week at 22p. Indeed, with such a fluid situation in terms of High Court judgements and general intrigue it is surprising that the stock has not been suspended until the company’s fate is resolved one way or the other. Apparently, the message in the current environment is that companies are only suspended to avoid investors making too much money, rather than preventing loss.
While it has been understandable that much of the focus in the medical world has been related to COVID-19, Tiziana Life Sciences (TILS) reminded us that there are other diseases to conquer. This came in the form of the biotechnology company announcing that the first patient with secondary progressive multiple sclerosis was dosed with nasally administered Foralumab, a fully human anti-CD3 monoclonal antibody, at Harvard Medical School, Boston, MA. This first-ever clinical study in SPMS patients, under an Individual Patient Expanded Access IND, will continue for six months. Shares of Tiziana were up 6.5p to 81p, helped by Chairman Gabriele Cerrone revealing he had taken his bonus in shares at 200p plus, rather than cash.